{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T18:30:34Z","timestamp":1791570634075,"version":"4.3.4"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,12,6]],"date-time":"2023-12-06T00:00:00Z","timestamp":1701820800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,12,6]],"date-time":"2023-12-06T00:00:00Z","timestamp":1701820800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CEN Case Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>A 62-year-old man with type 2 diabetes was admitted because of a decrease in estimated glomerular filtration rate from 72 to 17.5\u00a0mL\/min\/1.73\u00a0m<jats:sup>2<\/jats:sup> in 10\u00a0years and development of widespread bullous skin lesions. His hemoglobin A1c level had been maintained at 6.0\u20137.0% for 10\u00a0years with a dipeptidyl peptidase (DPP)-4 inhibitor. Skin biopsy showed typical bullous pemphigoid, and kidney biopsy showed tubulointerstitial nephritis with eosinophilic infiltration and glomerular endothelial cell proliferation. After discontinuing the DPP-4 inhibitor, skin lesions improved, and renal decline slowed. This case indicates that DPP-4 inhibitors can cause not only skin lesions but also renal disease.<\/jats:p>","DOI":"10.1007\/s13730-023-00835-1","type":"journal-article","created":{"date-parts":[[2023,12,6]],"date-time":"2023-12-06T10:02:19Z","timestamp":1701856939000},"page":"264-270","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["A case of bullous pemphigoid and renal disease after dipeptidyl peptidase 4 inhibitor administration"],"prefix":"10.1007","volume":"13","author":[{"given":"Atsuhiko","family":"Suenaga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Sawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Oba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Ikuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akinari","family":"Sekine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Yamanouchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiko","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Mizuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Suwabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobukazu","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Kono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichi","family":"Kinowaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Ohashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motoaki","family":"Miyazono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshifumi","family":"Ubara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,6]]},"reference":[{"key":"835_CR1","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1093\/ehjcvp\/pvv044","volume":"2","author":"F Remm","year":"2015","unstructured":"Remm F, Franz W, Brenner C. Gliptins and their target dipeptidyl peptidase 4: implications for the treatment of vascular disease. Eur Heart J Cardiovasc Pharmacother. 2015;2:185\u201393.","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"835_CR2","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1111\/j.1468-3083.2011.04062.x","volume":"26","author":"K Skandalis","year":"2012","unstructured":"Skandalis K, Spirova M, Gaitanis G, Tsartsarakis A, Bassukas ID. Drug-induced bullous pemphigoid in diabetes mellitus patients receiving dipeptidyl peptidase-IV inhibitors plus metformin. J Eur Acad Dermatol Venereol. 2012;26:249\u201353.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"835_CR3","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.3389\/fimmu.2019.01238","volume":"10","author":"K Tasanen","year":"2019","unstructured":"Tasanen K, Varpuluoma O, Nishie W. Dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid. Front Immunol. 2019;10:1238.","journal-title":"Front Immunol"},{"key":"835_CR4","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.ijcard.2015.07.044","volume":"199","author":"C Brenner","year":"2015","unstructured":"Brenner C, Franz WM, K\u00fchlenthal S, Kuschnerus K, Remm F, Gross L. DPP-4 inhibition ameliorates atherosclerosis by priming monocytes into M2 macrophages. Int J Cardiol. 2015;199:163\u20139.","journal-title":"Int J Cardiol"},{"issue":"4","key":"835_CR5","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1681\/ASN.2010010010","volume":"21","author":"TW Tervaert","year":"2010","unstructured":"Tervaert TW, Mooyaart AL, Amann K, Cohen AH, Cook HT, Drachenberg CB, Ferrario F, Fogo AB, Haas M, de Heer E, Joh K, No\u00ebl LH, Radhakrishnan J, Seshan SV, Bajema IM, Bruijn JA, Renal Pathology Society. Pathologic classification of diabetic nephropathy. J Am Soc Nephrol. 2010;21(4):556\u201363.","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"835_CR6","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1093\/ndt\/gft349","volume":"29","author":"K Mise","year":"2014","unstructured":"Mise K, Hoshino J, Ubara Y, Sumida K, Hiramatsu R, Hasegawa E, Yamanouchi M, Hayami N, Suwabe T, Sawa N, Fujii T, Ohashi K, Hara S, Takaichi K. Renal prognosis a long time after renal biopsy on patients with diabetic nephropathy. Nephrol Dial Transpl. 2014;29(1):109\u201318.","journal-title":"Nephrol Dial Transpl"},{"issue":"8","key":"835_CR7","doi-asserted-by":"publisher","first-page":"e0183190","DOI":"10.1371\/journal.pone.0183190","volume":"12","author":"K Mise","year":"2017","unstructured":"Mise K, Yamaguchi Y, Hoshino J, Ueno T, Sekine A, Sumida K, Yamanouchi M, Hayami N, Suwabe T, Hiramatsu R, Hasegawa E, Sawa N, Fujii T, Hara S, Sugiyama H, Makino H, Wada J, Ohashi K, Takaichi K, Ubara Y. Paratubular basement membrane insudative lesions predict renal prognosis in patients with type 2 diabetes and biopsy-proven diabetic nephropathy. PLoS ONE. 2017;12(8):e0183190.","journal-title":"PLoS ONE"},{"key":"835_CR8","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/j.ijcard.2015.08.056","volume":"202","author":"CJ Yang","year":"2016","unstructured":"Yang CJ, Fan ZX, Yang J, Yang J. DPP-4 inhibitors: a potential promising therapeutic target in prevention of atherosclerosis. Int J Cardiol. 2016;202:797\u20138.","journal-title":"Int J Cardiol"},{"issue":"11","key":"835_CR9","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1056\/NEJMoa0707330","volume":"358","author":"V Eremina","year":"2008","unstructured":"Eremina V, Jefferson JA, Kowalewska J, Hochster H, Haas M, Weisstuch J, Richardson C, Kopp JB, Kabir MG, Backx PH, Gerber HP, Ferrara N, Barisoni L, Alpers CE, Quaggin SE. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med. 2008;358(11):1129\u201336.","journal-title":"N Engl J Med"},{"issue":"9","key":"835_CR10","doi-asserted-by":"publisher","first-page":"e130","DOI":"10.2337\/dc18-0210","volume":"41","author":"M Arai","year":"2018","unstructured":"Arai M, Shirakawa J, Konishi H, Sagawa N, Terauchi Y. Bullous pemphigoid and dipeptidyl peptidase 4 inhibitors: a disproportionality analysis based on the Japanese adverse drug event report database. Diabetes Care. 2018;41(9):e130\u20132.","journal-title":"Diabetes Care"},{"issue":"3","key":"835_CR11","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/ki.2015.103","volume":"88","author":"S Shi","year":"2015","unstructured":"Shi S, Srivastava SP, Kanasaki M, He J, Kitada M, Nagai T, Nitta K, Takagi S, Kanasaki K, Koya D. Interactions of DPP-4 and integrin \u03b21 influences endothelial-to-mesenchymal transition. Kidney Int. 2015;88(3):479\u201389.","journal-title":"Kidney Int"}],"container-title":["CEN Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13730-023-00835-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13730-023-00835-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13730-023-00835-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T10:14:06Z","timestamp":1722507246000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13730-023-00835-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,6]]},"references-count":11,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,8]]}},"alternative-id":["835"],"URL":"https:\/\/doi.org\/10.1007\/s13730-023-00835-1","relation":{},"ISSN":["2192-4449"],"issn-type":[{"value":"2192-4449","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,6]]},"assertion":[{"value":"1 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing financial interests and no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The present report was produced in conformity with the Declaration of Helsinki, and the patient gave his written consent for this case report to be published.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}